Announced details
AI drug discovery, target molecule exploration and hypothesis generation, drug development, disease-related gene network analysis
Already adopted by multiple major pharmaceutical companies (cumulative number of companies: Not disclosed)
Norikazu Eiki (栄木 憲和) changed from no incumbent to strategic advisor for FRONTEO's life sciences AI business in the AI drug discovery field. No capital, personnel or business relationship is disclosed.
Former Chairman and Representative Director of Bayer Yakuhin Co., Ltd. From 2002 to 2014, he served as President and Representative Director and Chairman of Bayer Yakuhin, working from New Jersey, US, to connect US bioclusters with Japan. He is currently President of EIKI CONSULTING, LLC.
A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed)
New Jersey, US (Mr. Eiki's base)
The company states that it aims to expand and maximize the value of its life sciences AI business. The specific financial impact is Not disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT |
| Counterparty | Norikazu Eiki (栄木 憲和) (President, EIKI CONSULTING, LLC) |
| Counterparty overview | Former Chairman and Representative Director of Bayer Yakuhin Co., Ltd. From 2002 to 2014, he served as President and Representative Director and Chairman of Bayer Yakuhin, working from New Jersey, US, to connect US bioclusters with Japan. He is currently President of EIKI CONSULTING, LLC. |
| Relationship with the Company | Norikazu Eiki (栄木 憲和) changed from no incumbent to strategic advisor for FRONTEO's life sciences AI business in the AI drug discovery field. No capital, personnel or business relationship is disclosed. |
| Launch date | July 2026 (appointment as strategic advisor, track record) |
| Applicable area | AI drug discovery, target molecule exploration and hypothesis generation, drug development, disease-related gene network analysis |
| Registration number and expiry date | A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed) |
| Location | New Jersey, US (Mr. Eiki's base) |
| Usage history | Already adopted by multiple major pharmaceutical companies (cumulative number of companies: Not disclosed) |
| Impact on Business Performance | The company states that it aims to expand and maximize the value of its life sciences AI business. The specific financial impact is Not disclosed. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To use Mr. Eiki's management experience at global pharmaceutical companies, understanding of pharmaceutical regulatory and reimbursement systems in Japan and the US, and network with US bioclusters to accelerate the implementation of AI drug discovery in both markets and expand and maximize the value of the life sciences AI business.